UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact Name of Registrant as Specified in its Charter)
(State or Other Jurisdiction | (Commission | (IRS Employer |
(Address of Principal Executive Offices) (Zip Code)
Registrant’s telephone number, including area code: (
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
| Trading symbol(s) |
| Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.07 Submission of Matters to a Vote of Security Holders.
At the 2022 Annual Meeting of Stockholders of Kala Pharmaceuticals, Inc. (the “Company”) held on June 16, 2022, the Company’s stockholders voted on the following proposals:
1. | The Company’s stockholders elected Mr. Mark Iwicki and Dr. Mark S. Blumenkranz as Class II directors, each to serve for a three-year term expiring at the 2025 Annual Meeting of Stockholders and until his successor has been duly elected and qualified. The results of the stockholders’ vote with respect to the election of such Class II directors were as follows: |
| Votes For |
| Votes |
| Broker | |
Mark Iwicki | 30,738,402 | 2,509,262 | 13,897,318 | |||
Mark S. Blumenkranz | 31,930,406 | 1,317,258 | 13,897,318 |
2. | The Company’s stockholders ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022. The results of the stockholders’ vote with respect to such ratification were as follows: |
Votes For |
| Votes Against |
| Votes Abstaining |
| Broker Non- |
46,707,694 | 294,888 | 142,400 | 0 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| KALA PHARMACEUTICALS, INC. | |
|
|
|
Date: June 21, 2022 | By: | /s/ Eric L. Trachtenberg |
|
| Eric L. Trachtenberg |
|
| General Counsel, Chief Compliance Officer and Corporate Secretary |